CHMP minded to turn down Alzheimer’s drug Aduhelm, says BiogenBiogen and Eisai have said that the EMA’s human medicines committee looks unlikely recommended approval of their Alzheimer’s Share XCHMP minded to turn down Alzheimer’s drug Aduhelm, says Biogenhttps://pharmaphorum.com/news/chmp-minded-to-turn-down-alzheimers-drug-aduhelm-says-biogen/
Lilly files Alzheimer’s drug donanemab as Cortexyme rival fails trialEli Lilly has followed through on its plan to file for approval of its Alzheimer’s disease candidate donanemab, Share XLilly files Alzheimer’s drug donanemab as Cortexyme rival fails trialhttps://pharmaphorum.com/news/lilly-files-alzheimers-drug-donanemab-as-cortexyme-rival-fails-trial/
Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’sA software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in Share XEisai-backed trial will assess Altoida’s digital test for early Alzheimer’shttps://pharmaphorum.com/news/eisai-backed-trial-will-assess-altoidas-digital-test-for-early-alzheimers/
Biogen, Eisai double down on Alzheimer’s with lecanemab filingBiogen and Eisai’s first Alzheimer’s disease drug Aduhelm is facing an uphill battle in the US market, but Share XBiogen, Eisai double down on Alzheimer’s with lecanemab filinghttps://pharmaphorum.com/news/biogen-eisai-double-down-on-alzheimers-with-lecanemab-filing/
US health insurer will not fund Biogen, Eisai’s Alzheimer’s drug AduhelmHealth insurer Excellus BlueCross BlueShield has said it will not cover treatment with Biogen and Eisai’s new Alzheimer’s Share XUS health insurer will not fund Biogen, Eisai’s Alzheimer’s drug Aduhelmhttps://pharmaphorum.com/news/health-insurer-excellus-will-not-fund-alzheimers-drug-aduhelm/
Biogen adds real-world test for Aduhelm to its confirmatory trialBiogen and partner Eisai have said they will run a large-scale observational study of Alzheimer’s drug Aduhelm in Share XBiogen adds real-world test for Aduhelm to its confirmatory trialhttps://pharmaphorum.com/news/biogen-adds-real-world-test-for-aduhelm-to-its-confirmatory-trial/
FDA staffers defend Aduhelm approval in JAMA editorialThree FDA figures at the centre of the fallout over the approval Biogen and Eisai’s Alzheimer’s disease therapy Share XFDA staffers defend Aduhelm approval in JAMA editorialhttps://pharmaphorum.com/news/fda-staffers-defend-aduhelm-approval-in-jama-editorial/
US starts review of Aduhelm coverage amid fears of Medicare hitThe US government has started a review of how Biogen and Eisai’s pricey new Alzheimer’s disease therapy Aduhelm Share XUS starts review of Aduhelm coverage amid fears of Medicare hithttps://pharmaphorum.com/news/us-starts-review-of-aduhelm-coverage-amid-fears-of-medicare-hit/
Aduhelm approval controversy dials up as FDA seeks probeIn another twist to the Aduhelm approval tale, FDA’s Janet Woodcock has called for an independent investigation into Share XAduhelm approval controversy dials up as FDA seeks probehttps://pharmaphorum.com/news/aduhelm-approval-controversy-dials-up-as-fda-seeks-probe/
